Literature DB >> 28807217

Adenosine triphosphate as a molecular mediator of the vascular response to injury.

Christy M Guth1, Weifung Luo2, Olukemi Jolayemi2, Kalyan S Chadalavada2, Padmini Komalavilas3, Joyce Cheung-Flynn2, Colleen M Brophy4.   

Abstract

BACKGROUND: Human saphenous veins used for arterial bypass undergo stretch injury at the time of harvest and preimplant preparation. Vascular injury promotes intimal hyperplasia, the leading cause of graft failure, but the molecular events leading to this response are largely unknown. This study investigated adenosine triphosphate (ATP) as a potential molecular mediator in the vascular response to stretch injury, and the downstream effects of the purinergic receptor, P2X7R, and p38 MAPK activation.
MATERIALS AND METHODS: A subfailure stretch rat aorta model was used to determine the effect of stretch injury on release of ATP and vasomotor responses. Stretch-injured tissues were treated with apyrase, the P2X7R antagonist, A438079, or the p38 MAPK inhibitor, SB203580, and subsequent contractile forces were measured using a muscle bath. An exogenous ATP (eATP) injury model was developed and the experiment repeated. Change in p38 MAPK phosphorylation after stretch and eATP tissue injury was determined using Western blotting. Noninjured tissue was incubated in the p38 MAPK activator, anisomycin, and subsequent contractile function and p38 MAPK phosphorylation were analyzed.
RESULTS: Stretch injury was associated with release of ATP. Contractile function was decreased in tissue subjected to subfailure stretch, eATP, and anisomycin. Contractile function was restored by apyrase, P2X7R antagonism, and p38-MAPK inhibition. Stretch, eATP, and anisomycin-injured tissue demonstrated increased phosphorylation of p38 MAPK.
CONCLUSIONS: Taken together, these data suggest that the vascular response to stretch injury is associated with release of ATP and activation of the P2X7R/P38 MAPK pathway, resulting in contractile dysfunction. Modulation of this pathway in vein grafts after harvest and before implantation may reduce the vascular response to injury.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ATP; P2X7R; Subfailure stretch; Vascular injury; p38 MAPK

Mesh:

Substances:

Year:  2017        PMID: 28807217      PMCID: PMC5962343          DOI: 10.1016/j.jss.2017.03.025

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  25 in total

Review 1.  Pharmacology of cloned P2X receptors.

Authors:  R A North; A Surprenant
Journal:  Annu Rev Pharmacol Toxicol       Date:  2000       Impact factor: 13.820

2.  Upregulation of the P2X7 receptor after cryogenic injury to rat brain.

Authors:  Yong Yu; Yusuke Ishida; Shinya Ugawa; Takashi Ueda; Yuichi Oka; Kazuo Yamada; Shoichi Shimada
Journal:  Neuroreport       Date:  2009-03-04       Impact factor: 1.837

Review 3.  Regulation of cellular ATP release.

Authors:  J Gregory Fitz
Journal:  Trans Am Clin Climatol Assoc       Date:  2007

4.  Preservation solution impacts physiologic function and cellular viability of human saphenous vein graft.

Authors:  Eric S Wise; Kyle M Hocking; Susan Eagle; Tarek Absi; Padmini Komalavilas; Joyce Cheung-Flynn; Colleen M Brophy
Journal:  Surgery       Date:  2015-05-21       Impact factor: 3.982

5.  Surgical skin markers impair human saphenous vein graft smooth muscle and endothelial function.

Authors:  Susan Eagle; Colleen M Brophy; Padmini Komalavilas; Kyle Hocking; Gowthami Putumbaka; Michael Osgood; Kevin Sexton; Marzia Leacche; Joyce Cheung-Flynn
Journal:  Am Surg       Date:  2011-07       Impact factor: 0.688

6.  P2X7 receptor inhibition protects against ischemic acute kidney injury in mice.

Authors:  Yanli Yan; Jianwen Bai; Xiaoxu Zhou; Jinhua Tang; Chunming Jiang; Evelyn Tolbert; George Bayliss; Rujun Gong; Ting C Zhao; Shougang Zhuang
Journal:  Am J Physiol Cell Physiol       Date:  2015-01-14       Impact factor: 4.249

7.  Extracellular ATP triggers IL-1 beta release by activating the purinergic P2Z receptor of human macrophages.

Authors:  D Ferrari; P Chiozzi; S Falzoni; M Dal Susino; L Melchiorri; O R Baricordi; F Di Virgilio
Journal:  J Immunol       Date:  1997-08-01       Impact factor: 5.422

8.  Brilliant blue FCF is a nontoxic dye for saphenous vein graft marking that abrogates response to injury.

Authors:  Kyle M Hocking; Weifeng Luo; Fan Dong Li; Padmini Komalavilas; Colleen Brophy; Joyce Cheung-Flynn
Journal:  J Vasc Surg       Date:  2015-02-19       Impact factor: 4.268

9.  Secretion of intracellular IL-1 receptor antagonist (type 1) is dependent on P2X7 receptor activation.

Authors:  Heather L Wilson; Sheila E Francis; Steven K Dower; David C Crossman
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

10.  Activation of p38 mitogen-activated protein kinase attenuates Leishmania donovani infection in macrophages.

Authors:  Muthoni Junghae; John G Raynes
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

View more
  3 in total

1.  Blocking P2X7 receptor with AZ 10606120 exacerbates vascular hyperpermeability and inflammation in murine polymicrobial sepsis.

Authors:  Jamie E Meegan; Padmini Komalavilas; Joyce Cheung-Flynn; Tsz Wing Yim; Nathan D Putz; Jordan J Jesse; Kyle D Smith; Tatiana N Sidorova; Han Noo Ri Lee; Toria Tomasek; Ciara M Shaver; Lorraine B Ware; Colleen M Brophy; Julie A Bastarache
Journal:  Physiol Rep       Date:  2022-06

2.  Vascular surgical stretch injury leads to activation of P2X7 receptors and impaired endothelial function.

Authors:  Padmini Komalavilas; Weifeng Luo; Christy M Guth; Olukemi Jolayemi; Rachel I Bartelson; Joyce Cheung-Flynn; Colleen M Brophy
Journal:  PLoS One       Date:  2017-11-14       Impact factor: 3.240

3.  A cell permeant phosphopeptide mimetic of Niban inhibits p38 MAPK and restores endothelial function after injury.

Authors:  Tsz Wing Yim; Daniel Perling; Monica Polcz; Padmini Komalavilas; Colleen Brophy; Joyce Cheung-Flynn
Journal:  FASEB J       Date:  2020-05-12       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.